REAL-WORLD DATA
Software
CLINICAL EXPERTISE

Creating the standard for behavioral health

with best-in-class real-world evidence

Behavioral health needs better evidence to drive decision-making. There is currently no standardized way to measure symptoms or quality of care for behavioral health conditions, making innovation in the field difficult to achieve.

We know that real-world data and analytics can revolutionize the behavioral health landscape by unlocking new and much-needed evidence to guide decisions for successful treatment development, efficient care delivery, and improved patient outcomes.

That's why we've built the field's largest, most robust sourfe of clinical data for real-world data and a uniquely powerful evidence engine. We're ready to set the standard for behavioral health.

Back to top
Contact us
OUR DATA

Real-World Evidence for

Real-World impact

Gold-standard data, elevated evidence

We have captured and mapped de-identified data from patient electronic health records across the U.S. to create the NeuroBlu Data, a single source of truth that reflects how behavioral health care is delivered. This data powers NeuroBlu Analytics, Holmusk's evidence engine that enables researchers to build patient cohorts, conduct studies at an unprecedented level of granularity, and generate impactful evidence.

30,000,000+

patients

30+

geographically-diverse health systems

20+

years of longitudinal data

check icon

Longitudinal

Follow patients over time with over 20 years of data, spanning inpatient and outpatient sites, including hospitals, emergency rooms, and community psychiatry clinics.

check icon

Fit-for-purpose

Conduct observational studies with data that are curated and ready to address your most challenging research questions.

check icon

Comprehensive

Track patient functioning and outcomes and compare different groups of patients with standardized quantitative outcome measures.

Behavioral health conditions

  • Major depressive disorder

8.7M+ patients

  • Generalized anxiety disorder

3.6M+ patients

  • Attention deficit hyperactivity disorder

3.1M+ patients

  • Post-traumatic stress disorder

1.3M+ patients

  • Schizophrenia

386K+ patients

  • Bipolar I disorder

371K+ patients

  • Schizoaffective disorder

302K+ patients

  • Obsessive compulsive disorder

290K+ patients

  • Bipolar II disorder

258K+ patients

  • Borderline personality disorder

155K+ patients

    Behavioral health assessments

    • The NeuroBlu Database provides both composite scores for the below measures and responses for individual items within the scoring tools, enabling more granular research.
    • Brief Bipolar Disorder Symptom Scale (BDSS)
    • Brief Negative Symptom Assessment (BNSA)
    • Clinical Global Impressions (CGI-I/CGI-S)
    • Columbia-Suicide Severity Rating Scale (C-SSRS)
    • Global Assessment of Functioning (GAF)
    • Patient Health Questionnaire-9 (PHQ-9)
    • Positive Symptom Rating Scale (PSRS)
    • The Daily Living Activities–20 (DLA-20)
    • The Quick Inventory of Depressive Symptomatology (QIDS)

    Pharmacological treatments

    • The NeuroBlu Database contains information on both psychotherapy and pharmacologic treatments. These include:
    • Antidepressants
    • Antipsychotics
    • Anxiolytics
    • Hypnotics and sedatives
    • Mood stabilizers
    • Psycholeptics
    • Psychostimulants

    Enriched data for deeper clinical context

    The NeuroBlu Database is enriched through the application of natural language processing models—the first to be developed specifically for behavioral health.

    These models extract important information from unstructured clinical notes within the electronic health record and transform it into standardized measures, adding valuable context to research by making more fit-for-purpose data available than ever before.

    Symptoms

    Gain a comprehensive picture of patients' emotions, cognition, and behaviors with data on symptoms that are often not captured in the electronic health record, such as anhedonia for patients with major depressive disorder.

    External stressors

    Explore how life events and psychosocial environmental stressors impact patient outcomes and influence treatment response.

    Social determinants of health

    Better understand how social, relational, and occupational factors may impact behavioral health.
    OUR Solutions

    Holmusk offers a range of digital solutions aimed at harnessing real-world data to improve behavioral health. Whether you're a researcher, a clinician, or a payer, we have a data-driven solution for your challenges.

    NeuroBlu: Powerful insights in just a few clicks

    Software

    Access insights in just a few clicks with our user-friendly data analytics software, complete with no-code analytics capabilities and pre-designed study templates so you can get the answers you need faster.

    Clinical Expertise

    Conduct analysis within NeuroBlu Analytics alongside our team of clinical and data science experts, who will guide you through the design and execution of an end-to-end study tailored specifically to your organization's needs.

    Behavioral Health Conditions, including

    Behavioral Health Assessments

    Pharmacological Treatments

    Information on a wide variety of conditions, such as:

    Substance use disorders: 255k+ patients

    Major depressive disorder: 251k+ patients

    Bipolar disorder: 134k+ patients

    Attention-deficit/hyperactivity disorder: 82k+ patients

    Post-traumatic stress disorder: 63k+ patients

    Schizoaffective disorder: 34k+ patients

    Schizophrenia: 33k+ patients

    Borderline personality disorder: 19k+ patients

    Autism spectrum disorder: 16k+ patients

    Access to behavioral health assessments, enabling researchers to study disease severity and outcomes. These assessments include:

    Substance use disorders: 255k+ patients

    Major depressive disorder: 251k+ patients

    Bipolar disorder: 134k+ patients

    Attention-deficit/hyperactivity disorder: 82k+ patients

    Post-traumatic stress disorder: 63k+ patients

    Schizoaffective disorder: 34k+ patients

    Schizophrenia: 33k+ patients

    Borderline personality disorder: 19k+ patients

    Autism spectrum disorder: 16k+ patients

    Access to rich data on pharmacological treatments, giving researchers the ability to determine effectiveness of treatments for patient subsegments, and identify trends to inform precision psychiatry. These treatments include:

    Substance use disorders: 255k+ patients

    Major depressive disorder: 251k+ patients

    Bipolar disorder: 134k+ patients

    Attention-deficit/hyperactivity disorder: 82k+ patients

    Post-traumatic stress disorder: 63k+ patients

    Schizoaffective disorder: 34k+ patients

    Schizophrenia: 33k+ patients

    Borderline personality disorder: 19k+ patients

    Autism spectrum disorder: 16k+ patients

    Request A Demo

    Digital solutions to better leverage real-world data

    Make informed, data-driven decisions with our Management and Supervision Tool (MaST), a clinical decision support tool used in the U.K. that leverages data visualization and predictive analytics to prioritize individuals at risk of crisis and improve caseload management.

    Seamlessly integrate measurement-based care with an electronic health record designed specifically for data capture and visualization within psychiatry practices and other mental health clinics.

    Behavioral Health Conditions, including

    Behavioral Health Assessments

    Pharmacological Treatments

    Information on a wide variety of conditions, such as:

    Substance use disorders: 255k+ patients

    Major depressive disorder: 251k+ patients

    Bipolar disorder: 134k+ patients

    Attention-deficit/hyperactivity disorder: 82k+ patients

    Post-traumatic stress disorder: 63k+ patients

    Schizoaffective disorder: 34k+ patients

    Schizophrenia: 33k+ patients

    Borderline personality disorder: 19k+ patients

    Autism spectrum disorder: 16k+ patients

    Access to behavioral health assessments, enabling researchers to study disease severity and outcomes. These assessments include:

    Substance use disorders: 255k+ patients

    Major depressive disorder: 251k+ patients

    Bipolar disorder: 134k+ patients

    Attention-deficit/hyperactivity disorder: 82k+ patients

    Post-traumatic stress disorder: 63k+ patients

    Schizoaffective disorder: 34k+ patients

    Schizophrenia: 33k+ patients

    Borderline personality disorder: 19k+ patients

    Autism spectrum disorder: 16k+ patients

    Access to rich data on pharmacological treatments, giving researchers the ability to determine effectiveness of treatments for patient subsegments, and identify trends to inform precision psychiatry. These treatments include:

    Substance use disorders: 255k+ patients

    Major depressive disorder: 251k+ patients

    Bipolar disorder: 134k+ patients

    Attention-deficit/hyperactivity disorder: 82k+ patients

    Post-traumatic stress disorder: 63k+ patients

    Schizoaffective disorder: 34k+ patients

    Schizophrenia: 33k+ patients

    Borderline personality disorder: 19k+ patients

    Autism spectrum disorder: 16k+ patients

    LEARN MORE

    OUR VALUE

    Real-World Evidence for

    Real-World impact

    Collaborating across the behavioral health ecosystem

    Our solutions have been leveraged by a range of stakeholders who share our vision that better evidence can vastly improve behavioral health.

    R&D for drug development

    • Optimize trial design by leveraging data on symptoms and outcomes (e.g. CGI-S) to identify patients in the real world who meet study criteria
    • Validate design assumptions by tracking real-world outcomes of patient cohorts
    • Identify additional diagnoses as potential new targets for existing drugs

    Medical affairs

    • Characterize disease burden of specific sub-cohorts of behavioral health patients
    • Generate evidence to illustrate existing gaps in treatment and how new drugs of interest help bridge these gaps
    • Identify patients best suited for newly approved or launched drugs

    Market access and health economics & outcomes research

    • Obtain advanced characterization of factors that may inhibit success, such as predictors of poor outcomes, lack of tolerability, and adherence to treatment
    • Understand optimal positioning of new products or lifecycle management of existing products to inform communication to payers and health care providers
    • Identify patient segments that are eligible for new drugs and use real-world outcomes to inform formulary decision-making

    Payers and value-based care

    • Monitor behavioral health utilization to optimize management strategies and understand patient journeys
    • Track and analyze patient outcomes over time and assess the effectiveness of different treatments and interventions
    • Identify high-risk patients with predictive analytics for early interventions

    Holmusk has been recognized for innovation in behavioral health by:

    See How We Collaborate

    OUR WORK IN ACTION

    Follow the latest evolutions in real-world evidence

    Publications

    Explore recent peer-reviewed publications and conference abstracts that leverage NeuroBlu Data to share new real-world evidence with the scientific community.

    Read More

    News

    Catch up on the latest company announcements, including news about novel collaborations, innovative projects, awards, and more.

    Read More

    Thought leadership

    Curious about the latest developments in real-world evidence and mental health? Check out our blog, the Hol Picture, where leaders from across Holmusk share thoughts.

    Read More

    Stay Up to Date

    We’d love for you to come along on the journey of improving behavioral health with better evidence.

    Thank you! We will get back to you soon.
    Oops! Something went wrong while submitting the form.
    Our Work in Action

    Read More Publications

    INNOVATION & INSIGHTS

    Read More

    Curious about what’s happening in the real-world evidence space? Check out our blog, the Hol Picture, where we share takeaways from recent talks and weigh in on news involving real-world evidence and behavioral health.

    Publications

    Explore recent peer-reviewed publications and conference abstracts that leveraged NeuroBlu data to share new real-world evidence with the scientific community.

    Read More

    News

    Catch up on the latest company announcements, including news about novel collaborations, innovative projects, awards, and more.

    Read More

    Thought Leadership

    Curious about the latest developments in real-world evidence and mental health? Check out our blog, the Hol Picture, where leaders from across Holmusk share thoughts.

    Read More

    Stay Up-to-Date

    We’re making fast strides toward a reimagined future for behavioral health, and we’d love for you to come along on our journey.

    Thank you! We will get back to you soon.
    Oops! Something went wrong while submitting the form.